Viraday Tablet

Viraday Tablet – Patient Access Information (Named Patient Supply)

Overview

Viraday Tablet is a fixed dose antiviral combination used in the management of HIV (Human Immunodeficiency Virus) infection. It is supplied under named patient or case based access programs, where treatment is prescribed by a licensed physician for an individual patient with a documented medical need.

Viraday is used as part of long term antiretroviral therapy to help control HIV replication, support immune function, and reduce the risk of HIV related complications, including progression to AIDS (Acquired Immunodeficiency Syndrome).

This medicine is not supplied as a retail product and is made available only against valid medical documentation, in accordance with country specific import and patient access regulations.

---

Therapeutic Use

Viraday Tablet is indicated for:

• Management of HIV-1 infection

• Long term viral suppression under medical supervision

• Supporting immune system recovery in diagnosed patients

Treatment decisions, dosage, and duration are determined solely by the treating physician

---

Clinical Benefits in HIV Management

In patients diagnosed with HIV, Viraday Tablet:

• Inhibits replication of the HIV virus

• Helps lower viral load in the bloodstream

• Supports recovery and maintenance of CD4 (immune) cell counts

• Reduces the risk of opportunistic infections

Viraday does not cure HIV or AIDS and does not prevent transmission. Continuous medical monitoring and strict adherence to therapy are essential for optimal outcomes.

---

Safety & Side Effects

As with all antiretroviral therapies, side effects may occur. Many are mild and temporary, but patients should report persistent or severe reactions to their healthcare provider.

Commonly reported effects include:

• Gastrointestinal discomfort (nausea, vomiting, diarrhea, abdominal pain)

• Headache, dizziness, fatigue

• Sleep disturbances or unusual dreams

• Skin reactions or rash

• Mood changes, including anxiety or low mood

• Changes in laboratory parameters (such as lipase or white blood cell count)

Clinical monitoring is recommended throughout treatment.

---

Administration Guidance

• Viraday Tablet should be taken exactly as prescribed by a physician

• The tablet should be swallowed whole

• Often recommended to be taken on an empty stomach

• Missed doses can reduce treatment effectiveness and should be avoided

Patients must not alter dosage or discontinue therapy without medical advice.

---

Mechanism of Action

Viraday Tablet contains a combination of:

• Emtricitabine

• Tenofovir disoproxil fumarate

• Efavirenz

These agents work synergistically to block viral replication at different stages of the HIV life cycle, helping reduce viral load and support immune recovery.

---

Named Patient Supply Through Oddway International

Oddway International facilitates named patient access to Viraday Tablet for:

• Hospitals

• Treating physicians

• Licensed importers

• Individual patients with approved prescriptions

Supply is handled on a case by case basis, ensuring compliance with destination country regulations and ethical pharmaceutical supply standards.